Exercise intolerance in chronic heart failure: Mechanisms and therapies. Part II

European Journal of Preventive Cardiology

Volumn 17, Issue 6, 2010, Pages 643-648

  Piepoli, Massimo F ^a   Guazzi, Marco ^c   Boriani, Giuseppe ^d   Cicoira, Mariantonietta ^e   Corrá, Ugo ^f   Libera, Luciano Dalla ^l   Emdin, Michele ^g   Mele, Donato ⁱ   Passino, Claudio ^g,h   Vescovo, Giorgio ^j   Vigorito, Carlo ^k   Villani, Giovanni ^a   Agostoni, Piergiuseppe ^b  

^a GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f IRCCS   (Italy)

^g Fondazione G Monasterio CNR Regione   (Italy)

^h SCUOLA SUPERIORE SANT ANNA   (Italy)

ⁱ UNIVERSITY OF FERRARA   (Italy)

^j SAN BORTOLO HOSPITAL   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l CNR   (Italy)

more..

Author keywords

chronic heart failure; exercise testing; exercise tolerance; quality of life; rehabilitation

Indexed keywords

BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; NEBIVOLOL; VASODILATOR AGENT;

AEROBIC EXERCISE; ARTICLE; CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOPULMONARY EXERCISE TEST; CHEMORECEPTOR REFLEX; DRUG MECHANISM; ENDURANCE TRAINING; ERGOREFLEX; EXERCISE; HEART FAILURE; HUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REFLEX; STRESS;

CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DYSPNEA; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; MULTIPLE ORGAN FAILURE; MUSCLE FATIGUE; REFLEX; TREATMENT OUTCOME;

EID: 79851499475     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833f3aa5     Document Type: Article

References (53)

1. Narkiewicz K, Pesek CA, van de Borne PJ, Kato M, Somers VK. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation 1999; 100: 262–267.
2. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996; 93: 940–952.
3. Marin-Neto JA, Pintya AO, Gallo L Jr, Maciel BC. Abnormal baroreflex control of heart rate in decompensated congestive heart failure and reversal after compensation. Am J Cardiol 1991; 67: 604–610.
4. Giannoni A, Emdin M, Poletti R, Bramanti F, Prontera C, Piepoli M, Passino C. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne–Stokes respiration and arrhythmias. Clin Sci (Lond) 2008; 114: 489–497.
5. Chua TP, Clark AL, Amadi AA, Coats AJ. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1996; 27: 650–657.
6. Ponikowski PP, Chua TP, Francis DP, Capucci A, Coats AJ, Piepoli MF. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 2001; 104: 2324–2330.
7. Stickland MK, Morgan BJ, Dempsey JA. Carotid chemoreceptor modulation of sympathetic vasoconstrictor outflow during exercise in healthy humans. J Physiol 2008; 586: 1743–1754.
8. Piepoli M, Clark AL, Coats AJS. Muscle metaboreceptor in the hemodynamic, autonomic and ventilatory responses to exercise in men. Am J Physiol 1995; 38: H1428–H1436.
9. Middlekauff HR, Sinoway LI. Increased mechanoreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol 2007; 102: 492–494.
10. lellamo F, Sala-Mercado JA, Ichinose M, Hammond RL, Pallante M, Ichinose T, et al. Spontaneous baroreflex control of heart rate during exercise and muscle metaboreflex activation in heart failure. Am J Physiol Heart Circ Physiol 2007; 293: H1929–H1936.
11. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361: 1077–1083.
12. Anker SD, Ponikowski P, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683–693.
13. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–1053.
14. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in heart failure. Circulation 1992; 85: 1751–1759.
15. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zamboni M, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in non-cachectic chronic heart failure patients. J Am Coll Cardiol 2001; 37: 2080–2085.
16. Anker SD, Swan J, Volterrani M, Chua TP, Clark AL, Poole-Wilson PA, Coats AJ. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997; 18: 259–269.
17. Filippatos GS, Kanatselos C, Manolatos DD, Vougas B, Sideris A, Kardara D, et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. Int J Cardiol 2003; 90: 107–113.
18. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526–534.
19. Cicoira M, Bolger A, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumor necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001; 15: 80–86.
20. Piepoli MF, Kaczmarek A, Francis DP, Davies LC, Rauchhaus M, Jankowska EA, et al. Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 2006; 114: 126–134.
21. Francis GS, Rector TS. Maximal exercise tolerance as a therapeutic end point in heart failure – are we relying on the right measure? Am J Cardiol 1994; 73: 304–306.
22. Narang N, Swedberg K, Cleland JFG. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effects of ACE-inhibitors on exercise capacity. Eur Heart J 1996; 17: 120–134.
23. Guazzi M, Melzi G, Agostoni PG. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic and idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80: 1572–1576.
24. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136–2144.
25. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity, and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24: 1678–1687.
26. Engelmeier RS, O'Connel JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy. A double-blind randomized, placebo controlled trial. Circulation 1985; 72: 536–546.
27. Agostoni P, Contini M, Cattadori G, Apostolo A, Sciomer S, Bussotti M, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: is β selectivity relevant? Eur J Heart Fail 2007; 9: 827–833.
28. Kitaoka H, Takata J, Hitomi N, Furuno T, Seo H, Chikamori T, Doi YL. Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2000; 85: 658–660.
29. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997; 95: 1930–1936.
30. Mutlu GM, Koch WJ, Factor P. Alveolar epithelial a2-adrenergic receptors. Their role in regulation of alveolar active sodium transport. Am J Respir Crit Care Med 2004; 170: 1270–1275.
31. Agostoni PG, Contini M, Magini A, Apostolo A, Cattadori G, Bussotti M, et al. Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 2006; 8: 729–735.
32. Dickstein K, Cohen-Solal A, Filippatos G, Dickstein K, Cohen-Solal A, Filippatos G, et al. Task force for diagnosis and treatment of acute and chronic heart failure 2008 of European Society of cardiology. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J 2008; 29: 2388–2442.
33. Pina IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, et al. Exercise and heart failure: a statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107: 1210–1225.
34. Chiappa GR, Roseguini BT, Vieira PJC, Alves CN, Tavares A, Winkelmann ER, et al. Inspiratory muscle training improves blood flow to resting and exercising limbs in patients with chronic heart failure. J Am Coll Cardiol 2008; 51: 1663–1671.
35. Braith RW, Welsch MA, Feigenbaum MS, Kluess HA, Pepine CJ. Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol 1999; 34: 1170–1175.
36. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 653–663.
37. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure. A randomized trial. JAMA 2000; 283: 3095–3101.
38. Giannuzzi P, Temporelli PL, Corrá U; for the ELVD-CHF Study Group. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 2003; 108: 554–559.
39. Leosco D, Rengo G, laccarino G, Golino L, Marchese M, Fortunato F, et al. Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart. Cardiovasc Res 2008; 78: 385–394.
40. Hambrecht R, Wolff A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454–460.
41. Sarto P, Balducci E, Balconi G, Fiordaliso F, Merlo L, Tuzzato G, et al. Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure. J Card Fail 2007; 13: 701–708.
42. Braith RW, Beck DT. Resistance exercise: training adaptations and developing a safe exercise prescription. Heart Fail Rev 2008; 13: 69–79.
43. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99: 1173–1182.
44. Piepoli MF, Davos C, Francis DP, Coats AJ; for the ExtraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328: 189–195.
45. O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ etal.; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301: 1439–1450.
46. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502–2514.
47. Boriani G, Biffi M, Martignani C, Fallani F, Greco C, Grigioni F, et al. Cardiac resynchronization by pacing: an electrical treatment of heart failure. Int J Cardiol 2004; 94: 151–161.
48. De Marco T, Wolfel E, Feldman AM, Lowes B, Higginbotham MB, Ghali JK, et al. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study. J Card Fail 2008; 14: 9–18.
49. Auricchio A, Kloss M, Trautmann SI, Rodner S, Klein H. Exercise performance following cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. Am J Cardiol 2002; 89: 198–203.
50. Wasserman K, Sun XG, Hansen JE. Effect of biventricular pacing on the exercise pathophysiology of heart failure. Chest 2007; 132: 250–261.
51. Cattadori G, Giraldi F, Berti M, Carbucicchio C, Pepi M, Della Bella P, et al. Assessment of cardiac resynchronization therapy response. Int J Cardiol 2009; 136: 240–242.
52. Piepoli MF, Villani GQ, Corrá U, Aschieri D, Rusticali G. Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity. Pacing Clin Electrophysiol 2008; 31: 701–708.
53. Boriani G, Diemberger I, Biffi M, Martignani C, Valzania C, Ziacchi M, et al. Cardiac resynchronization therapy in clinical practice: need for electrical, mechanical, clinical and logistic synchronization. J Interv Card Electrophysiol 2006; 17: 215–224.